ArticleMedical decision making : an international journal of the Society for Medical Decision Making2026
A Microsimulation-Based Approach for Mitigating Societal Bias in Chronic Kidney Disease Data.
Article in Medical decision making : an international journal of the Society for Medical Decision Making, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Update of
Authors and funding
8 authors.
Funding
Abstract
PurposeThe data-generating mechanisms underlying health care data are infrequently considered, leading to inequitable equilibria being reinforced throughout the care continuum. As race-based criteria are reassessed, including in chronic kidney disease, the effect of those criteria on patterns of disease progression should also be reevaluated. We proposed a microsimulation model for attenuating societal bias in primary care chronic kidney disease data to study this.MethodsWe developed a continuous-time, discrete-event individual-level simulation model of kidney function decline, measured by estimated glomerular filtration rate (eGFR). The model simulates individual eGFR trajectories over time and enables generating counterfactual outcome distributions that would have been observed in the absence of race-based diagnosis and treatment criteria. eGFR decline is accelerated by hypertension, diabetes, and reaching chronic kidney disease stage 3a and can be delayed by interventions, which are applied based on eGFR level, measured with or without an adjustment for Black race. A Bayesian calibration procedure was applied to identify rates of eGFR decline corresponding to stage distributions in the cohort.ResultsUnder the counterfactual scenario without a race adjustment, Black individuals qualify for diagnosis earlier, and non-Black individuals later, than under the reference scenario with race adjustment. The difference was largest for earlier stages and smaller at each consecutive stage. We do not observe differences in life expectancy between the 2 scenarios.LimitationsLarge variability in the prevalence of treatment and heterogeneity in treatment effectiveness may affect our results.ConclusionsBeyond estimating the clinical consequences of the eGFR equation change, our work offers an alternative to previously proposed data-debiasing approaches. The simulated data can be used to inform future interventions and policy decisions.HighlightsWe developed a microsimulation model of chronic kidney disease progression with primary care data that reflect the effect of removing race-based diagnostic and treatment criteria.The removal of race-based diagnostic criteria in our simulations changed the timing of qualification for chronic kidney disease diagnosis, ranging from 0.6 y to 9.6 y, with opposite effects for Black and non-Black patients.The simulated differences in expected survival after removing the race adjustment did not exceed 2 mo among individuals who developed chronic kidney disease.The explicit representation of the data-generation process can help anticipate the effect that policy changes can have on clinical data distributions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.